01
Cash & equivalents increased 9.3%
Cash & equivalents changed +9.3% from the comparable as-filed period.
$17.1M→$18.7MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAnnovis Bio, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +9.3% from the comparable as-filed period.
Net income changed -138.3% from the comparable as-filed period.
Operating income changed -129.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ANVS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-097228SEC ↗8-KAug 14, 2026Period Aug 14, 20260001104659-26-097091SEC ↗8-KJul 10, 2026Period Jul 7, 20260001104659-26-082341SEC ↗8-KJun 17, 2026Period Jun 17, 20260001104659-26-075198SEC ↗4May 21, 2026Period May 20, 20260001104659-26-065311SEC ↗8-KMay 20, 2026Period May 20, 20260001104659-26-064514SEC ↗10-QMay 15, 2026Period Mar 31, 20260001104659-26-062626SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| May 20, 2026Filed May 21, 2026 | Hoffman Michael BDirector | Open Market PurchaseDirect | 2,562 | $2 | $4,484 | Form 4 ↗ |
| May 20, 2026Filed May 21, 2026 | Hoffman Michael BDirector | Open Market PurchaseDirect | 18,849 | $2 | $33,928 | Form 4 ↗ |
| May 20, 2026Filed May 21, 2026 | Hoffman Michael BDirector | Open Market PurchaseDirect | 54,933 | $2 | $104,367 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +132.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Stock-based compensation changed +223.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-062451